Back to top
more

Zai Lab Limited (ZLAB)

(Delayed Data from NSDQ)

$15.91 USD

15.91
364,581

+0.17 (1.08%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.94 +0.03 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ZLAB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Zai Lab Limited Unsponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 806 1,008 1,409 1,187 276
Receivables 59 40 47 5 4
Notes Receivable 6 9 7 0 0
Inventories 45 32 19 13 6
Other Current Assets 23 36 18 11 7
Total Current Assets 940 1,124 1,501 1,216 292
Net Property & Equipment 54 58 43 29 21
Investments & Advances 9 6 16 1 2
Other Non-Current Assets 0 0 24 22 14
Deferred Charges 0 0 0 0 0
Intangibles 16 8 10 9 9
Deposits & Other Assets 2 4 3 2 1
Total Assets 1,036 1,220 1,610 1,298 355
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 113 66 126 63 23
Current Portion Long-Term Debt 0 0 0 0 6
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 83 67 61 30 13
Total Current Liabilities 203 140 193 98 47
Mortgages 0 0 0 0 0
Deferred Taxes/Income 29 21 27 17 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 240 175 230 128 60
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,975 2,893 2,826 1,897 735
Retained Earnings -2,196 -1,861 -1,418 -714 -445
Other Equity 38 26 -24 -15 5
Treasury Stock 21 12 4 0 0
Total Shareholder's Equity 796 1,046 1,380 1,169 295
Total Liabilities & Shareholder's Equity 1,036 1,220 1,610 1,298 355
Total Common Equity 796 1,046 1,380 1,169 295
Shares Outstanding 98.80 97.90 96.40 NA 58.10
Book Value Per Share 8.06 10.68 14.31 -0.01 5.07

Fiscal Year End for Zai Lab Limited Unsponsored ADR falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 806 820 875 930
Receivables NA 59 42 47 43
Notes Receivable NA 6 24 21 17
Inventories NA 45 44 36 38
Other Current Assets NA 23 30 38 43
Total Current Assets NA 940 960 1,018 1,072
Net Property & Equipment NA 54 55 56 58
Investments & Advances NA 9 4 5 7
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 16 5 5 8
Deposits & Other Assets NA 2 3 4 4
Total Assets NA 1,036 1,044 1,106 1,170
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 113 55 67 66
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 83 63 59 51
Total Current Liabilities NA 203 125 133 125
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 29 28 29 31
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 240 163 174 169
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,975 2,954 2,932 2,911
Retained Earnings NA -2,196 -2,101 -2,031 -1,911
Other Equity NA 38 48 52 17
Treasury Stock NA 21 21 21 17
Total Shareholder's Equity NA 796 881 932 1,001
Total Liabilities & Shareholder's Equity NA 1,036 1,044 1,106 1,170
Total Common Equity 0 796 881 932 1,001
Shares Outstanding 99.20 98.80 98.80 98.30 97.90
Book Value Per Share 0.00 8.06 8.92 9.48 10.23